Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S, Kwatra SG, Silverberg JI, Simpson EL, Thyssen JP, Yosipovitch G, Zhang F, Cameron MC, Cella RR, Valdez H, DiBonaventura M, Feeney C. Ständer S, et al. Among authors: cameron mc. Am J Clin Dermatol. 2023 Jan;24(1):97-107. doi: 10.1007/s40257-022-00738-4. Epub 2022 Dec 13. Am J Clin Dermatol. 2023. PMID: 36512175 Free PMC article. Clinical Trial.
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Silverberg JI, et al. Among authors: cameron mc. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12. J Eur Acad Dermatol Venereol. 2021. PMID: 33991374 Free PMC article. Review.
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Kim BS, Silverberg JI, Ständer S, Yosipovitch G, Simpson EL, DiBonaventura M, Kerkmann U, Farooqui SA, Biswas P, Valdez H, Cameron MC. Kim BS, et al. Among authors: cameron mc. Dermatitis. 2021 Oct 1;32(1S):S39-S44. doi: 10.1097/DER.0000000000000770. Dermatitis. 2021. PMID: 34175862 Free PMC article.
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE.
Gooderham MJ, Chu CY, Rojo R, Valdez H, Biswas P, Cameron MC, Feeney C, Encinas GA, Peeples-Lamirande K, Cappelleri JC, Myers DE, DiBonaventura M. Gooderham MJ, et al. Among authors: cameron mc. JAAD Int. 2021 Jul 1;4:46-48. doi: 10.1016/j.jdin.2021.05.004. eCollection 2021 Sep. JAAD Int. 2021. PMID: 34409391 Free PMC article. No abstract available.
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Blauvelt A, et al. Among authors: cameron mc. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. J Am Acad Dermatol. 2022. PMID: 34416294 Free article. Clinical Trial.
Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C. Reich K, et al. Among authors: cameron mc. J Allergy Clin Immunol Pract. 2022 Dec;10(12):3228-3237.e2. doi: 10.1016/j.jaip.2022.08.042. Epub 2022 Sep 13. J Allergy Clin Immunol Pract. 2022. PMID: 36108923 Free article. Clinical Trial.
Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
Magnolo N, Cameron MC, Shahriari M, Geng B, Calimlim BM, Teixeira H, Hu X, Yang Y, Liu Y, Zhang S, Sancho Sanchez C, Altman K, Langley RG. Magnolo N, et al. Among authors: cameron mc. J Dermatolog Treat. 2024 Dec;35(1):2344589. doi: 10.1080/09546634.2024.2344589. Epub 2024 May 2. J Dermatolog Treat. 2024. PMID: 38697950 Free article. Clinical Trial.
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
Desai SR, Stein Gold L, Cameron MC, Golant A, Lewitt GM, Bruno MJ, Martin G, Brown PM, Rubenstein DS, Butners V, Tallman AM. Desai SR, et al. Among authors: cameron mc. Dermatol Ther (Heidelb). 2023 Oct;13(10):2443-2460. doi: 10.1007/s13555-023-01008-9. Epub 2023 Sep 11. Dermatol Ther (Heidelb). 2023. PMID: 37697121 Free PMC article.
33 results